News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
| Partners |
|
At Debiopharm Group, we have dedicated alliance managers to look after our partners. Disclosed principal partners include:
Aché, Aurigene, CAT, Dr. Reddy’s Laboratories, EMS Sigma Farma, Ferring, Ipsen, Kirin, LG Life Sciences, Medical futures, Nagoya University, NanoCarrier, Pfizer, Pharmaleads, Ranbaxy, Rowfarma, Salix, sanofi-aventis, Sidus, sigma-tau, TcLand, Tecnofarma, Tulane University, Tzamal Bio-Pharma,Yakult, Watson Pharmaceuticals
|